Immunity after yellow fever vaccination in travelers using immunosuppressive medication-YETI study

Completed

• Conditions: Yellow Fever infection; 10047438

• Registration Number: NL-OMON37037
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 75

Inclusion Criteria

> 18 years
Having been administered a Yellow Fever vaccination

Exclusion Criteria

< 18 years
Vaccination admnistered > 20 years prior

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The number of yellow fever specific CD8+ T cells in peripheral blood<br /><br>mononuclear cells (PBMCs)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Height and duration of antibody presence using the plaque reduction<br /><br>neutralization test;<br /><br>Rate of local and systemic adverse events</p><br>